Stockscreener 앱 받기
1.32
2.22%
-0.03
전일 마감가:
$1.35
열려 있는:
$1.34
하루 거래량:
2.06M
Relative Volume:
0.43
시가총액:
$354.10M
수익:
$232.40M
순이익/손실:
$-20.51M
주가수익비율:
-17.12
EPS:
-0.0771
순현금흐름:
$60.04M
1주 성능:
+8.20%
1개월 성능:
+15.79%
6개월 성능:
-6.38%
1년 성능:
-64.18%
1일 변동 폭
$1.295
$1.3491
1주일 범위
$1.22
$1.36
52주 변동 폭
$0.8227
$3.79
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.32 | 343.37M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics Inc (AKBA) Income Statement - TradingKey
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Akebia Therapeutics Inc (AKBA) Balance Sheet - TradingKey
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Akebia Therapeutics Inc (AKBA) Cash Flow - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.220| - TradingKey
Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.290|Chg%:+0.070 - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.280| - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9 - TradingView
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Brokerages - MarketBeat
Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Akebia Therapeutics (AKBA) Q2 2024 earnings summary - Quartr
Lobbying Update: $360,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) - Seeking Alpha
ETFs Investing in Akebia Therapeutics, Inc. Stocks - TradingView
Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Akebia Therapeutics Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesPre-Earnings Setup - DonanımHaber
Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics (AKBA) Proxy filing Summary - Quartr
Akebia Therapeutics (AKBA) Climbs 5.38% as Stock Nears Key Resistance ZoneWeak Sell Signals - dars.gov.et
AKBAAkebia Therapeutics Inc Options - Finviz
Chief Business Officer Erik Ostrowski Sold A Bunch Of Shares In Akebia Therapeutics - Moomoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $6.00 - GuruFocus
Akebia Therapeutics Fortifies Vafseo Patent Protection Through 2036, Strengthening Commercial ProspectsProduct Revenue Analysis - dars.gov.et
Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover - Stock Titan
H.C. Wainwright reiterates Akebia stock rating on trial results By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ostrowski Erik - Moomoo
Akebia TherapeuticsVoice Trial Meets Stopp - Moomoo
U.S. Renal Care and Akebia Therapeutics, Inc. Announce Interim Analysis of VOICE Trial Demonstrates Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo Versus ESA - marketscreener.com
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 - Yahoo Finance
Akebia (AKBA) VOICE Trial Halted Following Positive Interim Resu - GuruFocus
Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis - marketscreener.com
Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint - TradingView
Vafseo shows safer composite outcomes vs ESA in Akebia (AKBA) VOICE trial - Stock Titan
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - marketscreener.com
Vafseo trial stops early after safety win in dialysis patients - Stock Titan
Form 144 Akebia Therapeutics For: 29 June By Investing.com - Investing.com Australia
Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therap - The National Law Review
Akebia Therapeutics, Inc. (AKBA) Investigation: Bronstein, Gewirt - The National Law Review
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.08%
0.17%
자본화:
|
볼륨(24시간):